Romania Pharmaceuticals & Healthcare Q1 2019
The drug pricing environment, exemplified by the clawback tax, continues to pose considerable risks for drugmakers,limiting the Romanian pharmaceutical market's attractiveness. Access to medicines is poor, with a severe lack of public healthcarefinancing shifting the burden of costs onto patients. Having said this, pharmaceutical market growth remains on a robust trajectory,outperforming all EU member states, due to low levels of spending and shifting demand dynamics.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook